Patients with severe COVID-19 pneumonia treated with leukotriene inhibitors are more likely to survive
How a genetic mutation affects the body’s immune system response to viruses, development of blood cancers
25 May 2022Monkeypox: ‘too early to call it an epidemic’
25 May 2022Patients with severe COVID-19 pneumonia treated with leukotriene inhibitors are more likely to survive
University at Buffalo biomedical informatics researchers have found that patients hospitalized with COVID-19 pneumonia had a 13.5% survival advantage when treated with a combination of leukotriene inhibitors (LTIs) and the steroid dexamethasone.
